Vivani Medical announced the filing of a Registration Statement on Form S-1 with the U.S. SEC for the proposed initial public offering of Cortigent. Cortigent, currently a wholly-owned subsidiary of Vivani, was formed for the purpose of advancing the business of Vivani’s neuromodulation division and will continue to be controlled by Vivani following the initial public offering. Cortigent is led by its CEO, Jonathan Adams. ThinkEquity is acting as sole book-running manager for the proposed initial public offering.
Published first on TheFly
